Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06841614Phase 3Not Yet Recruiting

EBOla Post-Exposure Prophylaxis

Role: collaborator

NCT05202288Phase 2Not Yet Recruiting

Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers

Role: collaborator

NCT06613867Completed

Wakobo-ti-Kodro: Improving Identification of Pregnancy at Risk of Obstetric Complications at Community Level

Role: collaborator

NCT03655561Active Not Recruiting

Lassa Fever Clinical Course and Prognostic Factors in Nigeria

Role: collaborator

NCT04466241Phase 2Completed

Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial

Role: collaborator

NCT04920838Phase 2Unknown

Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection

Role: collaborator

All 6 trials loaded